Physician profile
Sandeep Kumar
NPI 1487180105
$769.16
in general payments reported to CMS, 2019-2025
14 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.17 · 2021: $83.23 · 2022: $119 · 2023: $166 · 2024: $97.71 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $195.89 | 2024-2025 | Terlivaz |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $129.06 | 2022-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.46 | 2022-2023 | Jardiance |
| Glaxosmithkline, LLC. | $62.55 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $44.03 | 2021-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $32.87 | 2025 | |
| Intercept Pharmaceuticals, INC. | $31.45 | 2022 | |
| Solventum Corporation | $30.60 | 2024 | V.A.C.Ulta |
| Merck Sharp & Dohme LLC | $27.28 | 2023 | Zerbaxa |
| Pfizer INC. | $25.66 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.07 | 2023 | Gattex |
| Abbvie INC. | $19.53 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.99 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $17.72 | 2024 | Lokelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.